Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy

被引:7
|
作者
Ishido, Kenji [1 ]
Azuma, Mizutomo [1 ]
Koizumi, Wasaburo [1 ]
Takeuchi, Atsuko [1 ]
Sakuramoto, Shinichi [2 ]
Watanabe, Masahiko [2 ]
Okayasu, Isao [3 ]
机构
[1] Kitasato Univ, Dept Gastroenterol, East Hosp, Kanagawa 2288520, Japan
[2] Kitasato Univ, Dept Surg, East Hosp, Kanagawa 2288520, Japan
[3] Kitasato Univ, Dept Pathol, East Hosp, Kanagawa 2288520, Japan
来源
PHARMACOGENETICS AND GENOMICS | 2009年 / 19卷 / 12期
关键词
advanced gastric cancer; S-1; thymidylate synthase; MESSENGER-RNA LEVEL; THYMIDYLATE SYNTHASE; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE-PHOSPHORYLASE; ORAL FLUOROPYRIMIDINE; PHASE-II; ADJUVANT CHEMOTHERAPY; EXPRESSION LEVELS; GENE-EXPRESSION; 5-FLUOROURACIL;
D O I
10.1097/FPC.0b013e328333351b
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Many studies have reported that low intratumoral mRNA expression of thymidylate synthase (TS) is an important biomarker of response to chemotherapy in patients with unresectable advanced gastric cancer. However, the role of gene expression profile of patients who received postoperative adjuvant chemotherapy remains unclear. In this study, we evaluated how TS and other associated genes related to outcome. Methods Seventy-nine patients with stage II or III advanced gastric cancer who underwent gastrectomy were analyzed. Thirty-nine patients received adjuvant chemotherapy with S-1 after surgery (S-1 group) and 40 patients underwent surgery only (surgery group). Formalin-fixed, paraffin-embedded tumor tissues were dissected by the laser-captured microdissection technique and analyzed for target gene expressions using a quantitative real-time polymerase chain reaction. Results There were no significant differences between the S-1 group and the surgery group in gene expressions except TS (P=0.034). In the S-1 group, recurrence-free survival (RFS) and overall survival (OS) were significantly longer in patients with low TS expression compared with patients with high TS expression (P=0.021 and 0.016), whereas there were no correlations in the surgery group. Furthermore, RFS and OS were both correlated with extent of lymph node metastasis (N) (P=0.038 and 0.020) and TS expression (P=0.021 and 0.032). On multivariate analysis it was found that TS expression and N were significant independent prognostic factors of RFS and OS (TS: P=0.027 and 0.050, N: P=0.048 and 0.032). Conclusion Our results suggested that intratumoral TS expression is an independent prognostic factor in patients with gastric cancer who received postoperative adjuvant chemotherapy with S-1. Pharmacogenetics and Genomics 19:955-964 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:955 / 964
页数:10
相关论文
共 50 条
  • [41] Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy
    Tamura, Shigeyuki
    Fujitani, Kazumasa
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    ONCOLOGY, 2011, 80 (5-6) : 296 - 300
  • [42] Prognostic impact of postoperative systemic inflammatory response in patients with stage II/III gastric cancer
    Kenji Kuroda
    Takahiro Toyokawa
    Yuichiro Miki
    Mami Yoshii
    Tatsuro Tamura
    Hiroaki Tanaka
    Shigeru Lee
    Kazuya Muguruma
    Masakazu Yashiro
    Masaichi Ohira
    Scientific Reports, 12
  • [43] Prognostic impact of postoperative systemic inflammatory response in patients with stage II/III gastric cancer
    Kuroda, Kenji
    Toyokawa, Takahiro
    Miki, Yuichiro
    Yoshii, Mami
    Tamura, Tatsuro
    Tanaka, Hiroaki
    Lee, Shigeru
    Muguruma, Kazuya
    Yashiro, Masakazu
    Ohira, Masaichi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Noriyuki Hirahara
    Takeshi Matsubara
    Shunsuke Kaji
    Tetsu Yamamoto
    Ryoji Hyakudomi
    Kiyoe Takai
    Kazunari Ishitobi
    Yuki Uchida
    Yoshitsugu Tajima
    BMC Cancer, 21
  • [46] Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
    K Yamaguchi
    T Shimamura
    I Hyodo
    W Koizumi
    T Doi
    H Narahara
    Y Komatsu
    T Kato
    S Saitoh
    T Akiya
    M Munakata
    Y Miyata
    Y Maeda
    H Takiuchi
    S Nakano
    T Esaki
    F Kinjo
    Y Sakata
    British Journal of Cancer, 2006, 94 : 1803 - 1808
  • [47] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Hirahara, Noriyuki
    Matsubara, Takeshi
    Kaji, Shunsuke
    Yamamoto, Tetsu
    Hyakudomi, Ryoji
    Takai, Kiyoe
    Ishitobi, Kazunari
    Uchida, Yuki
    Tajima, Yoshitsugu
    BMC CANCER, 2021, 21 (01)
  • [48] The impact of dose modification or termination of S-1 as adjuvant therapy on survival of locally advanced gastric cancer underwent curative gastrectomy.
    Kawakami, Takeshi
    Machida, Nozomu
    Bando, Etsuro
    Hayashi, Kaori
    Shirasu, Hiromichi
    Kawahira, Masahiro
    Kawai, Sadayuki
    Kito, Yosuke
    Yoshida, Yukio
    Hamauchi, Satoshi
    Todaka, Akiko
    Tsushima, Takahiro
    Yokota, Tomoya
    Yamazaki, Kentaro
    Fukutomi, Akira
    Terashima, Masanori
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [49] S-1 showed excellent clinical response against patients with advanced gastric cancer
    Taguchi, T
    Horikoshi, N
    Mitachi, Y
    Sakata, Y
    Sugimachi, K
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1585 - 1588
  • [50] Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer
    Kochi, Mitsugu
    Fuji, Masashi
    Kanamori, Noriaki
    Mihara, Yoshiaki
    Funada, Tomoya
    Tamegai, Hidenori
    Watanabe, Megumu
    Takayama, Yuriko
    Suda, Hiroshi
    Takayama, Tadatoshi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 17 - 21